CBUS (CBUS) Stock Analysis
Verdict: AVOID
Severe cash burn ($51M annual FCF deficit) and high debt ($268M) expose CBUS to imminent dilution risk despite Trait Machine IP potential.
Investment score: 24/100
The AI model views CBUS as a high-risk micro-cap biotechnology stock facing imminent liquidity pressure. With an annual FCF deficit of -$51.17M in 2025 and $9.92M cash at year-end, cash runway is under 3 months without external funding. Despite long-term Trait Machine ag-tech platform IP, financial solvency risks dominate near-term outlook.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| BMEA | -3.62 | 10.70 | 0.00 | -2.80 | — | 0.00 |
| VXRT | 3.14 | 1.38 | 0.47 | 1.50 | — | 0.16 |
| VTVT | -283.36 | 4.92 | 2.21 | 0.79 | — | -0.13 |
| INO | -1.07 | 23.34 | 0.00 | -0.97 | — | 0.00 |
| EQ | -7.37 | 3.77 | 0.00 | -3.43 | — | 0.00 |